VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies (Preprint)
Authors: Beaton Laura , Tregidgo Henry F J , Znati Sami A , Forsyth Sharon , Clarkson Matthew J , Bandula Steven , Chouhan Manil , Lowe Helen L , Zaw Thin May , Hague Julian , Sharma Dinesh , Pollok Joerg-Matthias , Davidson Brian R , Raja Jowad , Munneke Graham , Stuckey Daniel J , Bascal Zainab A , Wilde Paul E , Cooper Sarah , Ryan Samantha , Czuczman Peter , Boucher Eveline , Hartley John A , Lewis Andrew L , Jansen Marnix , Meyer Tim , Sharma Ricky A 
Published: March 2019

BACKGROUND

Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and is also a treatment option for patients with liver metastases from colorectal cancer. However, TACE is not a curative treatment, and tumor progression occurs in more than half of the patients treated. Despite advances and technical refinements of TACE, including the introduction of drug-eluting beads-TACE, the clinical efficacy of TACE has not been optimized, and improved arterial therapies are required.

OBJECTIVE

The primary objectives of the VEROnA study are to evaluate the safety and tolerability of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with resectable liver malignancies and to determine concentrations of vandetanib and the N-desmethyl metabolite in plasma and resected liver following treatment with BTG-002814.

METHODS

The VEROnA study is a first-in-human, open-label, single-arm, phase 0, window-of-opportunity study of BTG-002814 (containing 100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery in patients with resectable liver malignancies. Eligible patients have a diagnosis of colorectal liver metastases, or HCC (Childs Pugh A), diagnosed histologically or radiologically, and are candidates for liver surgery. All patients are followed up for 28 days following surgery. Secondary objectives of this study are to evaluate the anatomical distribution of BTG-002814 on noncontrast-enhanced imaging, to evaluate histopathological features in the surgical specimen, and to assess changes in blood flow on dynamic contrast-enhanced magnetic resonance imaging following treatment with BTG-002814. Exploratory objectives of this study are to study blood biomarkers with the potential to identify patients likely to respond to treatment and to correlate the distribution of BTG-002814 on imaging with pathology by 3-dimensional modeling.

RESULTS

Enrollment for the study was completed in February 2019. Results of a planned interim analysis were reviewed by a safety committee after the first 3 patients completed follow-up. The recommendation of the committee was to continue the study without any changes to the dose or trial design, as there were no significant unexpected toxicities related to BTG-002814.

CONCLUSIONS

The VEROnA study is studying the feasibility of administering BTG-002814 to optimize the use of this novel technology as liver-directed therapy for patients with primary and secondary liver cancer.

CLINICALTRIAL

ClinicalTrial.gov NCT03291379; https://clinicaltrials.gov/ct2/show/NCT03291379

INTERNATIONAL REGISTERED REPORT

DERR1-10.2196/13696